Diebold Nixdorf, Incorporated (DBD) Stock Competitors & Peer Comparison
See (DBD) competitors and their performances in Stock Market.
Peer Comparison Table: Software - Application Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| DBD | $81.14 | +0.12% | 2.8B | 27.99 | $2.90 | N/A |
| SAP | $181.79 | +3.61% | 212B | 25.03 | $7.27 | +1.61% |
| APP | $613.09 | +2.20% | 206B | 53.17 | $11.53 | N/A |
| CRM | $191.10 | +8.47% | 156.5B | 22.14 | $8.63 | +0.88% |
| SHOP | $118.71 | +3.20% | 154.2B | 116.49 | $1.02 | N/A |
| UBER | $70.40 | -0.73% | 143.2B | 17.46 | $4.03 | N/A |
| NOW | $124.37 | +14.38% | 128.3B | 73.61 | $1.69 | N/A |
| ADBE | $259.21 | +7.36% | 104.8B | 15.10 | $17.17 | N/A |
| CDNS | $374.93 | +0.29% | 103.4B | 87.62 | $4.28 | N/A |
| INTU | $331.53 | +5.92% | 90.7B | 20.22 | $16.40 | +1.41% |
Stock Comparison
DBD vs SAP Comparison June 2026
DBD plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DBD stands at 2.8B. In comparison, SAP has a market cap of 212B. Regarding current trading prices, DBD is priced at $81.14, while SAP trades at $181.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DBD currently has a P/E ratio of 27.99, whereas SAP's P/E ratio is 25.03. In terms of profitability, DBD's ROE is +0.10%, compared to SAP's ROE of +0.17%. Regarding short-term risk, DBD is less volatile compared to SAP. This indicates potentially lower risk in terms of short-term price fluctuations for DBD.Check SAP's competition here
DBD vs APP Comparison June 2026
DBD plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DBD stands at 2.8B. In comparison, APP has a market cap of 206B. Regarding current trading prices, DBD is priced at $81.14, while APP trades at $613.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DBD currently has a P/E ratio of 27.99, whereas APP's P/E ratio is 53.17. In terms of profitability, DBD's ROE is +0.10%, compared to APP's ROE of +2.22%. Regarding short-term risk, DBD is less volatile compared to APP. This indicates potentially lower risk in terms of short-term price fluctuations for DBD.Check APP's competition here
DBD vs CRM Comparison June 2026
DBD plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DBD stands at 2.8B. In comparison, CRM has a market cap of 156.5B. Regarding current trading prices, DBD is priced at $81.14, while CRM trades at $191.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DBD currently has a P/E ratio of 27.99, whereas CRM's P/E ratio is 22.14. In terms of profitability, DBD's ROE is +0.10%, compared to CRM's ROE of +0.15%. Regarding short-term risk, DBD is less volatile compared to CRM. This indicates potentially lower risk in terms of short-term price fluctuations for DBD.Check CRM's competition here
DBD vs SHOP Comparison June 2026
DBD plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DBD stands at 2.8B. In comparison, SHOP has a market cap of 154.2B. Regarding current trading prices, DBD is priced at $81.14, while SHOP trades at $118.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DBD currently has a P/E ratio of 27.99, whereas SHOP's P/E ratio is 116.49. In terms of profitability, DBD's ROE is +0.10%, compared to SHOP's ROE of +0.11%. Regarding short-term risk, DBD is less volatile compared to SHOP. This indicates potentially lower risk in terms of short-term price fluctuations for DBD.Check SHOP's competition here
DBD vs UBER Comparison June 2026
DBD plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DBD stands at 2.8B. In comparison, UBER has a market cap of 143.2B. Regarding current trading prices, DBD is priced at $81.14, while UBER trades at $70.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DBD currently has a P/E ratio of 27.99, whereas UBER's P/E ratio is 17.46. In terms of profitability, DBD's ROE is +0.10%, compared to UBER's ROE of +0.33%. Regarding short-term risk, DBD is less volatile compared to UBER. This indicates potentially lower risk in terms of short-term price fluctuations for DBD.Check UBER's competition here
DBD vs NOW Comparison June 2026
DBD plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DBD stands at 2.8B. In comparison, NOW has a market cap of 128.3B. Regarding current trading prices, DBD is priced at $81.14, while NOW trades at $124.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DBD currently has a P/E ratio of 27.99, whereas NOW's P/E ratio is 73.61. In terms of profitability, DBD's ROE is +0.10%, compared to NOW's ROE of +0.15%. Regarding short-term risk, DBD is less volatile compared to NOW. This indicates potentially lower risk in terms of short-term price fluctuations for DBD.Check NOW's competition here
DBD vs ADBE Comparison June 2026
DBD plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DBD stands at 2.8B. In comparison, ADBE has a market cap of 104.8B. Regarding current trading prices, DBD is priced at $81.14, while ADBE trades at $259.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DBD currently has a P/E ratio of 27.99, whereas ADBE's P/E ratio is 15.10. In terms of profitability, DBD's ROE is +0.10%, compared to ADBE's ROE of +0.62%. Regarding short-term risk, DBD is less volatile compared to ADBE. This indicates potentially lower risk in terms of short-term price fluctuations for DBD.Check ADBE's competition here
DBD vs CDNS Comparison June 2026
DBD plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DBD stands at 2.8B. In comparison, CDNS has a market cap of 103.4B. Regarding current trading prices, DBD is priced at $81.14, while CDNS trades at $374.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DBD currently has a P/E ratio of 27.99, whereas CDNS's P/E ratio is 87.62. In terms of profitability, DBD's ROE is +0.10%, compared to CDNS's ROE of +0.21%. Regarding short-term risk, DBD is more volatile compared to CDNS. This indicates potentially higher risk in terms of short-term price fluctuations for DBD.Check CDNS's competition here
DBD vs INTU Comparison June 2026
DBD plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DBD stands at 2.8B. In comparison, INTU has a market cap of 90.7B. Regarding current trading prices, DBD is priced at $81.14, while INTU trades at $331.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DBD currently has a P/E ratio of 27.99, whereas INTU's P/E ratio is 20.22. In terms of profitability, DBD's ROE is +0.10%, compared to INTU's ROE of +0.23%. Regarding short-term risk, DBD is less volatile compared to INTU. This indicates potentially lower risk in terms of short-term price fluctuations for DBD.Check INTU's competition here
DBD vs SNOW Comparison June 2026
DBD plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DBD stands at 2.8B. In comparison, SNOW has a market cap of 88.5B. Regarding current trading prices, DBD is priced at $81.14, while SNOW trades at $255.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DBD currently has a P/E ratio of 27.99, whereas SNOW's P/E ratio is -72.55. In terms of profitability, DBD's ROE is +0.10%, compared to SNOW's ROE of -0.56%. Regarding short-term risk, DBD is less volatile compared to SNOW. This indicates potentially lower risk in terms of short-term price fluctuations for DBD.Check SNOW's competition here
DBD vs DDOG Comparison June 2026
DBD plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DBD stands at 2.8B. In comparison, DDOG has a market cap of 88B. Regarding current trading prices, DBD is priced at $81.14, while DDOG trades at $247.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DBD currently has a P/E ratio of 27.99, whereas DDOG's P/E ratio is 650.92. In terms of profitability, DBD's ROE is +0.10%, compared to DDOG's ROE of +0.04%. Regarding short-term risk, DBD is less volatile compared to DDOG. This indicates potentially lower risk in terms of short-term price fluctuations for DBD.Check DDOG's competition here
DBD vs ADSK Comparison June 2026
DBD plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DBD stands at 2.8B. In comparison, ADSK has a market cap of 48.8B. Regarding current trading prices, DBD is priced at $81.14, while ADSK trades at $231.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DBD currently has a P/E ratio of 27.99, whereas ADSK's P/E ratio is 44.23. In terms of profitability, DBD's ROE is +0.10%, compared to ADSK's ROE of +0.49%. Regarding short-term risk, DBD is less volatile compared to ADSK. This indicates potentially lower risk in terms of short-term price fluctuations for DBD.Check ADSK's competition here
DBD vs MSTR Comparison June 2026
DBD plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DBD stands at 2.8B. In comparison, MSTR has a market cap of 47.3B. Regarding current trading prices, DBD is priced at $81.14, while MSTR trades at $159.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DBD currently has a P/E ratio of 27.99, whereas MSTR's P/E ratio is -4.30. In terms of profitability, DBD's ROE is +0.10%, compared to MSTR's ROE of -0.24%. Regarding short-term risk, DBD is less volatile compared to MSTR. This indicates potentially lower risk in terms of short-term price fluctuations for DBD.Check MSTR's competition here
DBD vs WDAY Comparison June 2026
DBD plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DBD stands at 2.8B. In comparison, WDAY has a market cap of 38.3B. Regarding current trading prices, DBD is priced at $81.14, while WDAY trades at $146.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DBD currently has a P/E ratio of 27.99, whereas WDAY's P/E ratio is 45.54. In terms of profitability, DBD's ROE is +0.10%, compared to WDAY's ROE of +0.10%. Regarding short-term risk, DBD is less volatile compared to WDAY. This indicates potentially lower risk in terms of short-term price fluctuations for DBD.Check WDAY's competition here
DBD vs ANSS Comparison June 2026
DBD plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DBD stands at 2.8B. In comparison, ANSS has a market cap of 32.9B. Regarding current trading prices, DBD is priced at $81.14, while ANSS trades at $374.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DBD currently has a P/E ratio of 27.99, whereas ANSS's P/E ratio is 55.53. In terms of profitability, DBD's ROE is +0.10%, compared to ANSS's ROE of +0.05%. Regarding short-term risk, DBD is more volatile compared to ANSS. This indicates potentially higher risk in terms of short-term price fluctuations for DBD.Check ANSS's competition here
DBD vs ROP Comparison June 2026
DBD plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DBD stands at 2.8B. In comparison, ROP has a market cap of 32.9B. Regarding current trading prices, DBD is priced at $81.14, while ROP trades at $325.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DBD currently has a P/E ratio of 27.99, whereas ROP's P/E ratio is 20.32. In terms of profitability, DBD's ROE is +0.10%, compared to ROP's ROE of +0.09%. Regarding short-term risk, DBD is less volatile compared to ROP. This indicates potentially lower risk in terms of short-term price fluctuations for DBD.Check ROP's competition here
DBD vs ZM Comparison June 2026
DBD plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DBD stands at 2.8B. In comparison, ZM has a market cap of 29.8B. Regarding current trading prices, DBD is priced at $81.14, while ZM trades at $101.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DBD currently has a P/E ratio of 27.99, whereas ZM's P/E ratio is 14.96. In terms of profitability, DBD's ROE is +0.10%, compared to ZM's ROE of +0.22%. Regarding short-term risk, DBD is less volatile compared to ZM. This indicates potentially lower risk in terms of short-term price fluctuations for DBD.Check ZM's competition here
DBD vs STRC Comparison June 2026
DBD plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DBD stands at 2.8B. In comparison, STRC has a market cap of 29.4B. Regarding current trading prices, DBD is priced at $81.14, while STRC trades at $98.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DBD currently has a P/E ratio of 27.99, whereas STRC's P/E ratio is N/A. In terms of profitability, DBD's ROE is +0.10%, compared to STRC's ROE of -0.24%. Regarding short-term risk, DBD is more volatile compared to STRC. This indicates potentially higher risk in terms of short-term price fluctuations for DBD.Check STRC's competition here
DBD vs STRF Comparison June 2026
DBD plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DBD stands at 2.8B. In comparison, STRF has a market cap of 29.3B. Regarding current trading prices, DBD is priced at $81.14, while STRF trades at $98.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DBD currently has a P/E ratio of 27.99, whereas STRF's P/E ratio is N/A. In terms of profitability, DBD's ROE is +0.10%, compared to STRF's ROE of -0.24%. Regarding short-term risk, DBD is less volatile compared to STRF. This indicates potentially lower risk in terms of short-term price fluctuations for DBD.Check STRF's competition here
DBD vs FICO Comparison June 2026
DBD plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DBD stands at 2.8B. In comparison, FICO has a market cap of 29B. Regarding current trading prices, DBD is priced at $81.14, while FICO trades at $1,250.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DBD currently has a P/E ratio of 27.99, whereas FICO's P/E ratio is 39.62. In terms of profitability, DBD's ROE is +0.10%, compared to FICO's ROE of -0.43%. Regarding short-term risk, DBD is less volatile compared to FICO. This indicates potentially lower risk in terms of short-term price fluctuations for DBD.Check FICO's competition here
DBD vs TEAM Comparison June 2026
DBD plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DBD stands at 2.8B. In comparison, TEAM has a market cap of 28.3B. Regarding current trading prices, DBD is priced at $81.14, while TEAM trades at $107.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DBD currently has a P/E ratio of 27.99, whereas TEAM's P/E ratio is -131.26. In terms of profitability, DBD's ROE is +0.10%, compared to TEAM's ROE of -0.17%. Regarding short-term risk, DBD is less volatile compared to TEAM. This indicates potentially lower risk in terms of short-term price fluctuations for DBD.Check TEAM's competition here
DBD vs STRK Comparison June 2026
DBD plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DBD stands at 2.8B. In comparison, STRK has a market cap of 20.9B. Regarding current trading prices, DBD is priced at $81.14, while STRK trades at $70.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DBD currently has a P/E ratio of 27.99, whereas STRK's P/E ratio is N/A. In terms of profitability, DBD's ROE is +0.10%, compared to STRK's ROE of -0.24%. Regarding short-term risk, DBD is less volatile compared to STRK. This indicates potentially lower risk in terms of short-term price fluctuations for DBD.Check STRK's competition here
DBD vs AZPN Comparison June 2026
DBD plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DBD stands at 2.8B. In comparison, AZPN has a market cap of 16.7B. Regarding current trading prices, DBD is priced at $81.14, while AZPN trades at $264.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DBD currently has a P/E ratio of 27.99, whereas AZPN's P/E ratio is 2403.00. In terms of profitability, DBD's ROE is +0.10%, compared to AZPN's ROE of -0.00%. Regarding short-term risk, DBD is more volatile compared to AZPN. This indicates potentially higher risk in terms of short-term price fluctuations for DBD.Check AZPN's competition here
DBD vs SSNC Comparison June 2026
DBD plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DBD stands at 2.8B. In comparison, SSNC has a market cap of 16.3B. Regarding current trading prices, DBD is priced at $81.14, while SSNC trades at $67.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DBD currently has a P/E ratio of 27.99, whereas SSNC's P/E ratio is 20.97. In terms of profitability, DBD's ROE is +0.10%, compared to SSNC's ROE of +0.12%. Regarding short-term risk, DBD is less volatile compared to SSNC. This indicates potentially lower risk in terms of short-term price fluctuations for DBD.Check SSNC's competition here
DBD vs PTC Comparison June 2026
DBD plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DBD stands at 2.8B. In comparison, PTC has a market cap of 16B. Regarding current trading prices, DBD is priced at $81.14, while PTC trades at $138.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DBD currently has a P/E ratio of 27.99, whereas PTC's P/E ratio is 13.33. In terms of profitability, DBD's ROE is +0.10%, compared to PTC's ROE of +0.33%. Regarding short-term risk, DBD is less volatile compared to PTC. This indicates potentially lower risk in terms of short-term price fluctuations for DBD.Check PTC's competition here
DBD vs GRAB Comparison June 2026
DBD plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DBD stands at 2.8B. In comparison, GRAB has a market cap of 14B. Regarding current trading prices, DBD is priced at $81.14, while GRAB trades at $3.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DBD currently has a P/E ratio of 27.99, whereas GRAB's P/E ratio is 88.50. In terms of profitability, DBD's ROE is +0.10%, compared to GRAB's ROE of +0.06%. Regarding short-term risk, DBD is less volatile compared to GRAB. This indicates potentially lower risk in terms of short-term price fluctuations for DBD.Check GRAB's competition here
DBD vs U Comparison June 2026
DBD plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DBD stands at 2.8B. In comparison, U has a market cap of 13.3B. Regarding current trading prices, DBD is priced at $81.14, while U trades at $30.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DBD currently has a P/E ratio of 27.99, whereas U's P/E ratio is -19.43. In terms of profitability, DBD's ROE is +0.10%, compared to U's ROE of -0.21%. Regarding short-term risk, DBD is less volatile compared to U. This indicates potentially lower risk in terms of short-term price fluctuations for DBD.Check U's competition here
DBD vs TYL Comparison June 2026
DBD plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DBD stands at 2.8B. In comparison, TYL has a market cap of 13.2B. Regarding current trading prices, DBD is priced at $81.14, while TYL trades at $313.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DBD currently has a P/E ratio of 27.99, whereas TYL's P/E ratio is 42.83. In terms of profitability, DBD's ROE is +0.10%, compared to TYL's ROE of +0.09%. Regarding short-term risk, DBD is less volatile compared to TYL. This indicates potentially lower risk in terms of short-term price fluctuations for DBD.Check TYL's competition here
DBD vs GWRE Comparison June 2026
DBD plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DBD stands at 2.8B. In comparison, GWRE has a market cap of 13B. Regarding current trading prices, DBD is priced at $81.14, while GWRE trades at $152.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DBD currently has a P/E ratio of 27.99, whereas GWRE's P/E ratio is 69.18. In terms of profitability, DBD's ROE is +0.10%, compared to GWRE's ROE of +0.13%. Regarding short-term risk, DBD is less volatile compared to GWRE. This indicates potentially lower risk in terms of short-term price fluctuations for DBD.Check GWRE's competition here
DBD vs FIG Comparison June 2026
DBD plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DBD stands at 2.8B. In comparison, FIG has a market cap of 12.4B. Regarding current trading prices, DBD is priced at $81.14, while FIG trades at $25.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DBD currently has a P/E ratio of 27.99, whereas FIG's P/E ratio is -6.45. In terms of profitability, DBD's ROE is +0.10%, compared to FIG's ROE of -1.01%. Regarding short-term risk, DBD is less volatile compared to FIG. This indicates potentially lower risk in terms of short-term price fluctuations for DBD.Check FIG's competition here
DBD vs DT Comparison June 2026
DBD plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DBD stands at 2.8B. In comparison, DT has a market cap of 12.4B. Regarding current trading prices, DBD is priced at $81.14, while DT trades at $42.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DBD currently has a P/E ratio of 27.99, whereas DT's P/E ratio is 78.92. In terms of profitability, DBD's ROE is +0.10%, compared to DT's ROE of +0.06%. Regarding short-term risk, DBD is less volatile compared to DT. This indicates potentially lower risk in terms of short-term price fluctuations for DBD.Check DT's competition here
DBD vs BKI Comparison June 2026
DBD plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DBD stands at 2.8B. In comparison, BKI has a market cap of 11.9B. Regarding current trading prices, DBD is priced at $81.14, while BKI trades at $75.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DBD currently has a P/E ratio of 27.99, whereas BKI's P/E ratio is 47.96. In terms of profitability, DBD's ROE is +0.10%, compared to BKI's ROE of +0.06%. Regarding short-term risk, DBD is more volatile compared to BKI. This indicates potentially higher risk in terms of short-term price fluctuations for DBD.Check BKI's competition here
DBD vs HUBS Comparison June 2026
DBD plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DBD stands at 2.8B. In comparison, HUBS has a market cap of 11.3B. Regarding current trading prices, DBD is priced at $81.14, while HUBS trades at $220.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DBD currently has a P/E ratio of 27.99, whereas HUBS's P/E ratio is 115.47. In terms of profitability, DBD's ROE is +0.10%, compared to HUBS's ROE of +0.05%. Regarding short-term risk, DBD is less volatile compared to HUBS. This indicates potentially lower risk in terms of short-term price fluctuations for DBD.Check HUBS's competition here
DBD vs DAY Comparison June 2026
DBD plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DBD stands at 2.8B. In comparison, DAY has a market cap of 11.2B. Regarding current trading prices, DBD is priced at $81.14, while DAY trades at $69.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DBD currently has a P/E ratio of 27.99, whereas DAY's P/E ratio is -73.54. In terms of profitability, DBD's ROE is +0.10%, compared to DAY's ROE of -0.06%. Regarding short-term risk, DBD is more volatile compared to DAY. This indicates potentially higher risk in terms of short-term price fluctuations for DBD.Check DAY's competition here
DBD vs XM Comparison June 2026
DBD plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DBD stands at 2.8B. In comparison, XM has a market cap of 11B. Regarding current trading prices, DBD is priced at $81.14, while XM trades at $18.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DBD currently has a P/E ratio of 27.99, whereas XM's P/E ratio is -10.43. In terms of profitability, DBD's ROE is +0.10%, compared to XM's ROE of -0.52%. Regarding short-term risk, DBD is more volatile compared to XM. This indicates potentially higher risk in terms of short-term price fluctuations for DBD.Check XM's competition here
DBD vs CDAY Comparison June 2026
DBD plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DBD stands at 2.8B. In comparison, CDAY has a market cap of 10.9B. Regarding current trading prices, DBD is priced at $81.14, while CDAY trades at $69.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DBD currently has a P/E ratio of 27.99, whereas CDAY's P/E ratio is 2317.33. In terms of profitability, DBD's ROE is +0.10%, compared to CDAY's ROE of -0.06%. Regarding short-term risk, DBD is less volatile compared to CDAY. This indicates potentially lower risk in terms of short-term price fluctuations for DBD.Check CDAY's competition here
DBD vs DOCU Comparison June 2026
DBD plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DBD stands at 2.8B. In comparison, DOCU has a market cap of 10.2B. Regarding current trading prices, DBD is priced at $81.14, while DOCU trades at $52.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DBD currently has a P/E ratio of 27.99, whereas DOCU's P/E ratio is 35.49. In terms of profitability, DBD's ROE is +0.10%, compared to DOCU's ROE of +0.16%. Regarding short-term risk, DBD is less volatile compared to DOCU. This indicates potentially lower risk in terms of short-term price fluctuations for DBD.Check DOCU's competition here
DBD vs FROG Comparison June 2026
DBD plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DBD stands at 2.8B. In comparison, FROG has a market cap of 9.6B. Regarding current trading prices, DBD is priced at $81.14, while FROG trades at $79.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DBD currently has a P/E ratio of 27.99, whereas FROG's P/E ratio is -149.96. In terms of profitability, DBD's ROE is +0.10%, compared to FROG's ROE of -0.07%. Regarding short-term risk, DBD is less volatile compared to FROG. This indicates potentially lower risk in terms of short-term price fluctuations for DBD.Check FROG's competition here
DBD vs BSY Comparison June 2026
DBD plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DBD stands at 2.8B. In comparison, BSY has a market cap of 9.5B. Regarding current trading prices, DBD is priced at $81.14, while BSY trades at $32.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DBD currently has a P/E ratio of 27.99, whereas BSY's P/E ratio is 37.52. In terms of profitability, DBD's ROE is +0.10%, compared to BSY's ROE of +0.24%. Regarding short-term risk, DBD is less volatile compared to BSY. This indicates potentially lower risk in terms of short-term price fluctuations for DBD.Check BSY's competition here
DBD vs YMM Comparison June 2026
DBD plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DBD stands at 2.8B. In comparison, YMM has a market cap of 9.2B. Regarding current trading prices, DBD is priced at $81.14, while YMM trades at $8.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DBD currently has a P/E ratio of 27.99, whereas YMM's P/E ratio is 14.97. In terms of profitability, DBD's ROE is +0.10%, compared to YMM's ROE of +0.10%. Regarding short-term risk, DBD is less volatile compared to YMM. This indicates potentially lower risk in terms of short-term price fluctuations for DBD.Check YMM's competition here
DBD vs MANH Comparison June 2026
DBD plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DBD stands at 2.8B. In comparison, MANH has a market cap of 8.9B. Regarding current trading prices, DBD is priced at $81.14, while MANH trades at $150.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DBD currently has a P/E ratio of 27.99, whereas MANH's P/E ratio is 42.03. In terms of profitability, DBD's ROE is +0.10%, compared to MANH's ROE of +0.78%. Regarding short-term risk, DBD is less volatile compared to MANH. This indicates potentially lower risk in terms of short-term price fluctuations for DBD.Check MANH's competition here
DBD vs OCFT Comparison June 2026
DBD plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DBD stands at 2.8B. In comparison, OCFT has a market cap of 8.6B. Regarding current trading prices, DBD is priced at $81.14, while OCFT trades at $7.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DBD currently has a P/E ratio of 27.99, whereas OCFT's P/E ratio is -3.01. In terms of profitability, DBD's ROE is +0.10%, compared to OCFT's ROE of -0.26%. Regarding short-term risk, DBD is more volatile compared to OCFT. This indicates potentially higher risk in terms of short-term price fluctuations for DBD.Check OCFT's competition here
DBD vs NATI Comparison June 2026
DBD plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DBD stands at 2.8B. In comparison, NATI has a market cap of 8B. Regarding current trading prices, DBD is priced at $81.14, while NATI trades at $59.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DBD currently has a P/E ratio of 27.99, whereas NATI's P/E ratio is 44.44. In terms of profitability, DBD's ROE is +0.10%, compared to NATI's ROE of +0.12%. Regarding short-term risk, DBD is more volatile compared to NATI. This indicates potentially higher risk in terms of short-term price fluctuations for DBD.Check NATI's competition here
DBD vs SMAR Comparison June 2026
DBD plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DBD stands at 2.8B. In comparison, SMAR has a market cap of 7.9B. Regarding current trading prices, DBD is priced at $81.14, while SMAR trades at $56.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DBD currently has a P/E ratio of 27.99, whereas SMAR's P/E ratio is -806.71. In terms of profitability, DBD's ROE is +0.10%, compared to SMAR's ROE of -0.19%. Regarding short-term risk, DBD is more volatile compared to SMAR. This indicates potentially higher risk in terms of short-term price fluctuations for DBD.Check SMAR's competition here
DBD vs PAYC Comparison June 2026
DBD plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DBD stands at 2.8B. In comparison, PAYC has a market cap of 7.6B. Regarding current trading prices, DBD is priced at $81.14, while PAYC trades at $139.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DBD currently has a P/E ratio of 27.99, whereas PAYC's P/E ratio is 16.16. In terms of profitability, DBD's ROE is +0.10%, compared to PAYC's ROE of +0.31%. Regarding short-term risk, DBD is less volatile compared to PAYC. This indicates potentially lower risk in terms of short-term price fluctuations for DBD.Check PAYC's competition here
DBD vs PCOR Comparison June 2026
DBD plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DBD stands at 2.8B. In comparison, PCOR has a market cap of 7.5B. Regarding current trading prices, DBD is priced at $81.14, while PCOR trades at $49.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DBD currently has a P/E ratio of 27.99, whereas PCOR's P/E ratio is -96.98. In terms of profitability, DBD's ROE is +0.10%, compared to PCOR's ROE of -0.06%. Regarding short-term risk, DBD is less volatile compared to PCOR. This indicates potentially lower risk in terms of short-term price fluctuations for DBD.Check PCOR's competition here
DBD vs CWAN Comparison June 2026
DBD plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DBD stands at 2.8B. In comparison, CWAN has a market cap of 7.2B. Regarding current trading prices, DBD is priced at $81.14, while CWAN trades at $24.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DBD currently has a P/E ratio of 27.99, whereas CWAN's P/E ratio is -135.14. In terms of profitability, DBD's ROE is +0.10%, compared to CWAN's ROE of -0.02%. Regarding short-term risk, DBD is more volatile compared to CWAN. This indicates potentially higher risk in terms of short-term price fluctuations for DBD.Check CWAN's competition here
DBD vs TTAN Comparison June 2026
DBD plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DBD stands at 2.8B. In comparison, TTAN has a market cap of 6.9B. Regarding current trading prices, DBD is priced at $81.14, while TTAN trades at $72.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DBD currently has a P/E ratio of 27.99, whereas TTAN's P/E ratio is -41.83. In terms of profitability, DBD's ROE is +0.10%, compared to TTAN's ROE of -0.11%. Regarding short-term risk, DBD is less volatile compared to TTAN. This indicates potentially lower risk in terms of short-term price fluctuations for DBD.Check TTAN's competition here
DBD vs ESTC Comparison June 2026
DBD plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DBD stands at 2.8B. In comparison, ESTC has a market cap of 6.7B. Regarding current trading prices, DBD is priced at $81.14, while ESTC trades at $64.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DBD currently has a P/E ratio of 27.99, whereas ESTC's P/E ratio is 18.86. In terms of profitability, DBD's ROE is +0.10%, compared to ESTC's ROE of +0.37%. Regarding short-term risk, DBD is less volatile compared to ESTC. This indicates potentially lower risk in terms of short-term price fluctuations for DBD.Check ESTC's competition here
DBD vs IDCC Comparison June 2026
DBD plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DBD stands at 2.8B. In comparison, IDCC has a market cap of 6.5B. Regarding current trading prices, DBD is priced at $81.14, while IDCC trades at $252.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DBD currently has a P/E ratio of 27.99, whereas IDCC's P/E ratio is 24.05. In terms of profitability, DBD's ROE is +0.10%, compared to IDCC's ROE of +0.33%. Regarding short-term risk, DBD is less volatile compared to IDCC. This indicates potentially lower risk in terms of short-term price fluctuations for DBD.Check IDCC's competition here
DBD vs DSGX Comparison June 2026
DBD plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DBD stands at 2.8B. In comparison, DSGX has a market cap of 6.3B. Regarding current trading prices, DBD is priced at $81.14, while DSGX trades at $73.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DBD currently has a P/E ratio of 27.99, whereas DSGX's P/E ratio is 39.47. In terms of profitability, DBD's ROE is +0.10%, compared to DSGX's ROE of +0.11%. Regarding short-term risk, DBD is less volatile compared to DSGX. This indicates potentially lower risk in terms of short-term price fluctuations for DBD.Check DSGX's competition here
DBD vs PCTY Comparison June 2026
DBD plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DBD stands at 2.8B. In comparison, PCTY has a market cap of 6.2B. Regarding current trading prices, DBD is priced at $81.14, while PCTY trades at $114.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DBD currently has a P/E ratio of 27.99, whereas PCTY's P/E ratio is 24.56. In terms of profitability, DBD's ROE is +0.10%, compared to PCTY's ROE of +0.22%. Regarding short-term risk, DBD is less volatile compared to PCTY. This indicates potentially lower risk in terms of short-term price fluctuations for DBD.Check PCTY's competition here
DBD vs COUP Comparison June 2026
DBD plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DBD stands at 2.8B. In comparison, COUP has a market cap of 6.1B. Regarding current trading prices, DBD is priced at $81.14, while COUP trades at $80.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DBD currently has a P/E ratio of 27.99, whereas COUP's P/E ratio is -17.99. In terms of profitability, DBD's ROE is +0.10%, compared to COUP's ROE of +0.00%. Regarding short-term risk, DBD is more volatile compared to COUP. This indicates potentially higher risk in terms of short-term price fluctuations for DBD.Check COUP's competition here
DBD vs PEGA Comparison June 2026
DBD plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DBD stands at 2.8B. In comparison, PEGA has a market cap of 6B. Regarding current trading prices, DBD is priced at $81.14, while PEGA trades at $35.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DBD currently has a P/E ratio of 27.99, whereas PEGA's P/E ratio is 19.31. In terms of profitability, DBD's ROE is +0.10%, compared to PEGA's ROE of +0.50%. Regarding short-term risk, DBD is less volatile compared to PEGA. This indicates potentially lower risk in terms of short-term price fluctuations for DBD.Check PEGA's competition here
DBD vs OTEX Comparison June 2026
DBD plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DBD stands at 2.8B. In comparison, OTEX has a market cap of 5.8B. Regarding current trading prices, DBD is priced at $81.14, while OTEX trades at $23.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DBD currently has a P/E ratio of 27.99, whereas OTEX's P/E ratio is 11.57. In terms of profitability, DBD's ROE is +0.10%, compared to OTEX's ROE of +0.13%. Regarding short-term risk, DBD is less volatile compared to OTEX. This indicates potentially lower risk in terms of short-term price fluctuations for DBD.Check OTEX's competition here
DBD vs APPF Comparison June 2026
DBD plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DBD stands at 2.8B. In comparison, APPF has a market cap of 5.8B. Regarding current trading prices, DBD is priced at $81.14, while APPF trades at $161.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DBD currently has a P/E ratio of 27.99, whereas APPF's P/E ratio is 38.47. In terms of profitability, DBD's ROE is +0.10%, compared to APPF's ROE of +0.31%. Regarding short-term risk, DBD is less volatile compared to APPF. This indicates potentially lower risk in terms of short-term price fluctuations for DBD.Check APPF's competition here
DBD vs ZETA Comparison June 2026
DBD plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DBD stands at 2.8B. In comparison, ZETA has a market cap of 5.7B. Regarding current trading prices, DBD is priced at $81.14, while ZETA trades at $22.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DBD currently has a P/E ratio of 27.99, whereas ZETA's P/E ratio is -229.00. In terms of profitability, DBD's ROE is +0.10%, compared to ZETA's ROE of -0.03%. Regarding short-term risk, DBD is less volatile compared to ZETA. This indicates potentially lower risk in terms of short-term price fluctuations for DBD.Check ZETA's competition here
DBD vs YOU Comparison June 2026
DBD plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DBD stands at 2.8B. In comparison, YOU has a market cap of 5.6B. Regarding current trading prices, DBD is priced at $81.14, while YOU trades at $55.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DBD currently has a P/E ratio of 27.99, whereas YOU's P/E ratio is 44.37. In terms of profitability, DBD's ROE is +0.10%, compared to YOU's ROE of +0.77%. Regarding short-term risk, DBD is less volatile compared to YOU. This indicates potentially lower risk in terms of short-term price fluctuations for DBD.Check YOU's competition here
DBD vs NICE Comparison June 2026
DBD plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DBD stands at 2.8B. In comparison, NICE has a market cap of 5.4B. Regarding current trading prices, DBD is priced at $81.14, while NICE trades at $92.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DBD currently has a P/E ratio of 27.99, whereas NICE's P/E ratio is 10.99. In terms of profitability, DBD's ROE is +0.10%, compared to NICE's ROE of +0.14%. Regarding short-term risk, DBD is less volatile compared to NICE. This indicates potentially lower risk in terms of short-term price fluctuations for DBD.Check NICE's competition here
DBD vs LYFT Comparison June 2026
DBD plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DBD stands at 2.8B. In comparison, LYFT has a market cap of 5.4B. Regarding current trading prices, DBD is priced at $81.14, while LYFT trades at $14.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DBD currently has a P/E ratio of 27.99, whereas LYFT's P/E ratio is 2.06. In terms of profitability, DBD's ROE is +0.10%, compared to LYFT's ROE of +1.50%. Regarding short-term risk, DBD is less volatile compared to LYFT. This indicates potentially lower risk in terms of short-term price fluctuations for DBD.Check LYFT's competition here
DBD vs GTLB Comparison June 2026
DBD plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DBD stands at 2.8B. In comparison, GTLB has a market cap of 5.2B. Regarding current trading prices, DBD is priced at $81.14, while GTLB trades at $31.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DBD currently has a P/E ratio of 27.99, whereas GTLB's P/E ratio is -91.32. In terms of profitability, DBD's ROE is +0.10%, compared to GTLB's ROE of -0.06%. Regarding short-term risk, DBD is less volatile compared to GTLB. This indicates potentially lower risk in terms of short-term price fluctuations for DBD.Check GTLB's competition here
DBD vs DUOL Comparison June 2026
DBD plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DBD stands at 2.8B. In comparison, DUOL has a market cap of 5.2B. Regarding current trading prices, DBD is priced at $81.14, while DUOL trades at $111.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DBD currently has a P/E ratio of 27.99, whereas DUOL's P/E ratio is 12.75. In terms of profitability, DBD's ROE is +0.10%, compared to DUOL's ROE of +0.34%. Regarding short-term risk, DBD is less volatile compared to DUOL. This indicates potentially lower risk in terms of short-term price fluctuations for DBD.Check DUOL's competition here
DBD vs NAVN Comparison June 2026
DBD plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DBD stands at 2.8B. In comparison, NAVN has a market cap of 5.1B. Regarding current trading prices, DBD is priced at $81.14, while NAVN trades at $21.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DBD currently has a P/E ratio of 27.99, whereas NAVN's P/E ratio is -5.25. In terms of profitability, DBD's ROE is +0.10%, compared to NAVN's ROE of -1.58%. Regarding short-term risk, DBD is less volatile compared to NAVN. This indicates potentially lower risk in terms of short-term price fluctuations for DBD.Check NAVN's competition here
DBD vs COMP Comparison June 2026
DBD plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DBD stands at 2.8B. In comparison, COMP has a market cap of 5B. Regarding current trading prices, DBD is priced at $81.14, while COMP trades at $8.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DBD currently has a P/E ratio of 27.99, whereas COMP's P/E ratio is 411.75. In terms of profitability, DBD's ROE is +0.10%, compared to COMP's ROE of +0.01%. Regarding short-term risk, DBD is less volatile compared to COMP. This indicates potentially lower risk in terms of short-term price fluctuations for DBD.Check COMP's competition here
DBD vs CVLT Comparison June 2026
DBD plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DBD stands at 2.8B. In comparison, CVLT has a market cap of 4.9B. Regarding current trading prices, DBD is priced at $81.14, while CVLT trades at $118.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DBD currently has a P/E ratio of 27.99, whereas CVLT's P/E ratio is 75.16. In terms of profitability, DBD's ROE is +0.10%, compared to CVLT's ROE of +0.35%. Regarding short-term risk, DBD is less volatile compared to CVLT. This indicates potentially lower risk in terms of short-term price fluctuations for DBD.Check CVLT's competition here
DBD vs GBTG Comparison June 2026
DBD plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DBD stands at 2.8B. In comparison, GBTG has a market cap of 4.9B. Regarding current trading prices, DBD is priced at $81.14, while GBTG trades at $9.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DBD currently has a P/E ratio of 27.99, whereas GBTG's P/E ratio is 58.41. In terms of profitability, DBD's ROE is +0.10%, compared to GBTG's ROE of +0.06%. Regarding short-term risk, DBD is more volatile compared to GBTG. This indicates potentially higher risk in terms of short-term price fluctuations for DBD.Check GBTG's competition here
DBD vs OCTVV Comparison June 2026
DBD plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DBD stands at 2.8B. In comparison, OCTVV has a market cap of 4.7B. Regarding current trading prices, DBD is priced at $81.14, while OCTVV trades at $17.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DBD currently has a P/E ratio of 27.99, whereas OCTVV's P/E ratio is 15.20. In terms of profitability, DBD's ROE is +0.10%, compared to OCTVV's ROE of N/A. Regarding short-term risk, DBD is less volatile compared to OCTVV. This indicates potentially lower risk in terms of short-term price fluctuations for DBD.Check OCTVV's competition here
DBD vs GRND-WT Comparison June 2026
DBD plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DBD stands at 2.8B. In comparison, GRND-WT has a market cap of 4.4B. Regarding current trading prices, DBD is priced at $81.14, while GRND-WT trades at $6.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DBD currently has a P/E ratio of 27.99, whereas GRND-WT's P/E ratio is N/A. In terms of profitability, DBD's ROE is +0.10%, compared to GRND-WT's ROE of +1.23%. Regarding short-term risk, DBD is more volatile compared to GRND-WT. This indicates potentially higher risk in terms of short-term price fluctuations for DBD.Check GRND-WT's competition here
DBD vs MNDY Comparison June 2026
DBD plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DBD stands at 2.8B. In comparison, MNDY has a market cap of 4.3B. Regarding current trading prices, DBD is priced at $81.14, while MNDY trades at $83.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DBD currently has a P/E ratio of 27.99, whereas MNDY's P/E ratio is 36.54. In terms of profitability, DBD's ROE is +0.10%, compared to MNDY's ROE of +0.11%. Regarding short-term risk, DBD is less volatile compared to MNDY. This indicates potentially lower risk in terms of short-term price fluctuations for DBD.Check MNDY's competition here
DBD vs CVT Comparison June 2026
DBD plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DBD stands at 2.8B. In comparison, CVT has a market cap of 4.2B. Regarding current trading prices, DBD is priced at $81.14, while CVT trades at $8.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DBD currently has a P/E ratio of 27.99, whereas CVT's P/E ratio is -40.57. In terms of profitability, DBD's ROE is +0.10%, compared to CVT's ROE of -0.06%. Regarding short-term risk, DBD is more volatile compared to CVT. This indicates potentially higher risk in terms of short-term price fluctuations for DBD.Check CVT's competition here
DBD vs PYCR Comparison June 2026
DBD plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DBD stands at 2.8B. In comparison, PYCR has a market cap of 4.1B. Regarding current trading prices, DBD is priced at $81.14, while PYCR trades at $22.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DBD currently has a P/E ratio of 27.99, whereas PYCR's P/E ratio is -187.42. In terms of profitability, DBD's ROE is +0.10%, compared to PYCR's ROE of -0.05%. Regarding short-term risk, DBD is more volatile compared to PYCR. This indicates potentially higher risk in terms of short-term price fluctuations for DBD.Check PYCR's competition here
DBD vs BTDR Comparison June 2026
DBD plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DBD stands at 2.8B. In comparison, BTDR has a market cap of 4.1B. Regarding current trading prices, DBD is priced at $81.14, while BTDR trades at $17.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DBD currently has a P/E ratio of 27.99, whereas BTDR's P/E ratio is -10.65. In terms of profitability, DBD's ROE is +0.10%, compared to BTDR's ROE of -0.70%. Regarding short-term risk, DBD is less volatile compared to BTDR. This indicates potentially lower risk in terms of short-term price fluctuations for DBD.Check BTDR's competition here
DBD vs RUM Comparison June 2026
DBD plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DBD stands at 2.8B. In comparison, RUM has a market cap of 4B. Regarding current trading prices, DBD is priced at $81.14, while RUM trades at $9.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DBD currently has a P/E ratio of 27.99, whereas RUM's P/E ratio is -21.37. In terms of profitability, DBD's ROE is +0.10%, compared to RUM's ROE of -0.38%. Regarding short-term risk, DBD is less volatile compared to RUM. This indicates potentially lower risk in terms of short-term price fluctuations for DBD.Check RUM's competition here
DBD vs SRAD Comparison June 2026
DBD plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DBD stands at 2.8B. In comparison, SRAD has a market cap of 3.9B. Regarding current trading prices, DBD is priced at $81.14, while SRAD trades at $13.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DBD currently has a P/E ratio of 27.99, whereas SRAD's P/E ratio is 50.81. In terms of profitability, DBD's ROE is +0.10%, compared to SRAD's ROE of +0.07%. Regarding short-term risk, DBD is less volatile compared to SRAD. This indicates potentially lower risk in terms of short-term price fluctuations for DBD.Check SRAD's competition here
DBD vs SOUN Comparison June 2026
DBD plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DBD stands at 2.8B. In comparison, SOUN has a market cap of 3.9B. Regarding current trading prices, DBD is priced at $81.14, while SOUN trades at $9.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DBD currently has a P/E ratio of 27.99, whereas SOUN's P/E ratio is -12.86. In terms of profitability, DBD's ROE is +0.10%, compared to SOUN's ROE of -0.40%. Regarding short-term risk, DBD is less volatile compared to SOUN. This indicates potentially lower risk in terms of short-term price fluctuations for DBD.Check SOUN's competition here
DBD vs RNG Comparison June 2026
DBD plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DBD stands at 2.8B. In comparison, RNG has a market cap of 3.8B. Regarding current trading prices, DBD is priced at $81.14, while RNG trades at $43.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DBD currently has a P/E ratio of 27.99, whereas RNG's P/E ratio is 46.06. In terms of profitability, DBD's ROE is +0.10%, compared to RNG's ROE of -0.17%. Regarding short-term risk, DBD is less volatile compared to RNG. This indicates potentially lower risk in terms of short-term price fluctuations for DBD.Check RNG's competition here
DBD vs PWSC Comparison June 2026
DBD plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DBD stands at 2.8B. In comparison, PWSC has a market cap of 3.8B. Regarding current trading prices, DBD is priced at $81.14, while PWSC trades at $22.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DBD currently has a P/E ratio of 27.99, whereas PWSC's P/E ratio is -67.09. In terms of profitability, DBD's ROE is +0.10%, compared to PWSC's ROE of -0.02%. Regarding short-term risk, DBD is more volatile compared to PWSC. This indicates potentially higher risk in terms of short-term price fluctuations for DBD.Check PWSC's competition here
DBD vs DAVE Comparison June 2026
DBD plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DBD stands at 2.8B. In comparison, DAVE has a market cap of 3.8B. Regarding current trading prices, DBD is priced at $81.14, while DAVE trades at $282.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DBD currently has a P/E ratio of 27.99, whereas DAVE's P/E ratio is 18.14. In terms of profitability, DBD's ROE is +0.10%, compared to DAVE's ROE of +0.85%. Regarding short-term risk, DBD is less volatile compared to DAVE. This indicates potentially lower risk in terms of short-term price fluctuations for DBD.Check DAVE's competition here
DBD vs BOX Comparison June 2026
DBD plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DBD stands at 2.8B. In comparison, BOX has a market cap of 3.7B. Regarding current trading prices, DBD is priced at $81.14, while BOX trades at $26.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DBD currently has a P/E ratio of 27.99, whereas BOX's P/E ratio is 42.14. In terms of profitability, DBD's ROE is +0.10%, compared to BOX's ROE of +1.51%. Regarding short-term risk, DBD is less volatile compared to BOX. This indicates potentially lower risk in terms of short-term price fluctuations for DBD.Check BOX's competition here
DBD vs BILL Comparison June 2026
DBD plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DBD stands at 2.8B. In comparison, BILL has a market cap of 3.7B. Regarding current trading prices, DBD is priced at $81.14, while BILL trades at $37.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DBD currently has a P/E ratio of 27.99, whereas BILL's P/E ratio is -160.91. In terms of profitability, DBD's ROE is +0.10%, compared to BILL's ROE of +0.00%. Regarding short-term risk, DBD is less volatile compared to BILL. This indicates potentially lower risk in terms of short-term price fluctuations for DBD.Check BILL's competition here
DBD vs KC Comparison June 2026
DBD plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DBD stands at 2.8B. In comparison, KC has a market cap of 3.6B. Regarding current trading prices, DBD is priced at $81.14, while KC trades at $12.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DBD currently has a P/E ratio of 27.99, whereas KC's P/E ratio is -24.08. In terms of profitability, DBD's ROE is +0.10%, compared to KC's ROE of -0.12%. Regarding short-term risk, DBD is less volatile compared to KC. This indicates potentially lower risk in terms of short-term price fluctuations for DBD.Check KC's competition here
DBD vs AYX Comparison June 2026
DBD plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DBD stands at 2.8B. In comparison, AYX has a market cap of 3.5B. Regarding current trading prices, DBD is priced at $81.14, while AYX trades at $48.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DBD currently has a P/E ratio of 27.99, whereas AYX's P/E ratio is -19.15. In terms of profitability, DBD's ROE is +0.10%, compared to AYX's ROE of -0.98%. Regarding short-term risk, DBD is more volatile compared to AYX. This indicates potentially higher risk in terms of short-term price fluctuations for DBD.Check AYX's competition here
DBD vs ENV Comparison June 2026
DBD plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DBD stands at 2.8B. In comparison, ENV has a market cap of 3.5B. Regarding current trading prices, DBD is priced at $81.14, while ENV trades at $63.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DBD currently has a P/E ratio of 27.99, whereas ENV's P/E ratio is -13.21. In terms of profitability, DBD's ROE is +0.10%, compared to ENV's ROE of -0.36%. Regarding short-term risk, DBD is more volatile compared to ENV. This indicates potentially higher risk in terms of short-term price fluctuations for DBD.Check ENV's competition here
DBD vs STUB Comparison June 2026
DBD plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DBD stands at 2.8B. In comparison, STUB has a market cap of 3.5B. Regarding current trading prices, DBD is priced at $81.14, while STUB trades at $9.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DBD currently has a P/E ratio of 27.99, whereas STUB's P/E ratio is -1.91. In terms of profitability, DBD's ROE is +0.10%, compared to STUB's ROE of -0.94%. Regarding short-term risk, DBD is less volatile compared to STUB. This indicates potentially lower risk in terms of short-term price fluctuations for DBD.Check STUB's competition here
DBD vs INST Comparison June 2026
DBD plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DBD stands at 2.8B. In comparison, INST has a market cap of 3.5B. Regarding current trading prices, DBD is priced at $81.14, while INST trades at $23.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DBD currently has a P/E ratio of 27.99, whereas INST's P/E ratio is -63.78. In terms of profitability, DBD's ROE is +0.10%, compared to INST's ROE of -0.03%. Regarding short-term risk, DBD is more volatile compared to INST. This indicates potentially higher risk in terms of short-term price fluctuations for DBD.Check INST's competition here
DBD vs LIF Comparison June 2026
DBD plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DBD stands at 2.8B. In comparison, LIF has a market cap of 3.4B. Regarding current trading prices, DBD is priced at $81.14, while LIF trades at $42.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DBD currently has a P/E ratio of 27.99, whereas LIF's P/E ratio is 24.28. In terms of profitability, DBD's ROE is +0.10%, compared to LIF's ROE of +0.31%. Regarding short-term risk, DBD is less volatile compared to LIF. This indicates potentially lower risk in terms of short-term price fluctuations for DBD.Check LIF's competition here
DBD vs ZI Comparison June 2026
DBD plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DBD stands at 2.8B. In comparison, ZI has a market cap of 3.4B. Regarding current trading prices, DBD is priced at $81.14, while ZI trades at $9.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DBD currently has a P/E ratio of 27.99, whereas ZI's P/E ratio is 77.92. In terms of profitability, DBD's ROE is +0.10%, compared to ZI's ROE of +0.08%. Regarding short-term risk, DBD is less volatile compared to ZI. This indicates potentially lower risk in terms of short-term price fluctuations for DBD.Check ZI's competition here
DBD vs BULL Comparison June 2026
DBD plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DBD stands at 2.8B. In comparison, BULL has a market cap of 3.4B. Regarding current trading prices, DBD is priced at $81.14, while BULL trades at $6.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DBD currently has a P/E ratio of 27.99, whereas BULL's P/E ratio is -5.11. In terms of profitability, DBD's ROE is +0.10%, compared to BULL's ROE of -0.01%. Regarding short-term risk, DBD is less volatile compared to BULL. This indicates potentially lower risk in terms of short-term price fluctuations for DBD.Check BULL's competition here
DBD vs NATL Comparison June 2026
DBD plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DBD stands at 2.8B. In comparison, NATL has a market cap of 3.3B. Regarding current trading prices, DBD is priced at $81.14, while NATL trades at $44.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DBD currently has a P/E ratio of 27.99, whereas NATL's P/E ratio is 19.92. In terms of profitability, DBD's ROE is +0.10%, compared to NATL's ROE of +0.48%. Regarding short-term risk, DBD is more volatile compared to NATL. This indicates potentially higher risk in terms of short-term price fluctuations for DBD.Check NATL's competition here
DBD vs QTWO Comparison June 2026
DBD plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DBD stands at 2.8B. In comparison, QTWO has a market cap of 3B. Regarding current trading prices, DBD is priced at $81.14, while QTWO trades at $47.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DBD currently has a P/E ratio of 27.99, whereas QTWO's P/E ratio is 41.88. In terms of profitability, DBD's ROE is +0.10%, compared to QTWO's ROE of +0.12%. Regarding short-term risk, DBD is less volatile compared to QTWO. This indicates potentially lower risk in terms of short-term price fluctuations for DBD.Check QTWO's competition here
DBD vs ADEA Comparison June 2026
DBD plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DBD stands at 2.8B. In comparison, ADEA has a market cap of 2.9B. Regarding current trading prices, DBD is priced at $81.14, while ADEA trades at $26.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DBD currently has a P/E ratio of 27.99, whereas ADEA's P/E ratio is 24.52. In terms of profitability, DBD's ROE is +0.10%, compared to ADEA's ROE of +0.28%. Regarding short-term risk, DBD is less volatile compared to ADEA. This indicates potentially lower risk in terms of short-term price fluctuations for DBD.Check ADEA's competition here
DBD vs PTRN Comparison June 2026
DBD plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DBD stands at 2.8B. In comparison, PTRN has a market cap of 2.9B. Regarding current trading prices, DBD is priced at $81.14, while PTRN trades at $18.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DBD currently has a P/E ratio of 27.99, whereas PTRN's P/E ratio is -23.20. In terms of profitability, DBD's ROE is +0.10%, compared to PTRN's ROE of -0.26%. Regarding short-term risk, DBD is less volatile compared to PTRN. This indicates potentially lower risk in terms of short-term price fluctuations for DBD.Check PTRN's competition here
DBD vs BRZE Comparison June 2026
DBD plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DBD stands at 2.8B. In comparison, BRZE has a market cap of 2.9B. Regarding current trading prices, DBD is priced at $81.14, while BRZE trades at $25.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DBD currently has a P/E ratio of 27.99, whereas BRZE's P/E ratio is -22.88. In terms of profitability, DBD's ROE is +0.10%, compared to BRZE's ROE of -0.20%. Regarding short-term risk, DBD is less volatile compared to BRZE. This indicates potentially lower risk in terms of short-term price fluctuations for DBD.Check BRZE's competition here
DBD vs WK Comparison June 2026
DBD plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DBD stands at 2.8B. In comparison, WK has a market cap of 2.8B. Regarding current trading prices, DBD is priced at $81.14, while WK trades at $49.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DBD currently has a P/E ratio of 27.99, whereas WK's P/E ratio is 207.50. In terms of profitability, DBD's ROE is +0.10%, compared to WK's ROE of -0.47%. Regarding short-term risk, DBD is less volatile compared to WK. This indicates potentially lower risk in terms of short-term price fluctuations for DBD.Check WK's competition here
DBD vs FSLY Comparison June 2026
DBD plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DBD stands at 2.8B. In comparison, FSLY has a market cap of 2.8B. Regarding current trading prices, DBD is priced at $81.14, while FSLY trades at $17.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DBD currently has a P/E ratio of 27.99, whereas FSLY's P/E ratio is -25.75. In terms of profitability, DBD's ROE is +0.10%, compared to FSLY's ROE of -0.11%. Regarding short-term risk, DBD is less volatile compared to FSLY. This indicates potentially lower risk in terms of short-term price fluctuations for DBD.Check FSLY's competition here
DBD vs BRUN Comparison June 2026
DBD plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DBD stands at 2.8B. In comparison, BRUN has a market cap of 2.7B. Regarding current trading prices, DBD is priced at $81.14, while BRUN trades at $34.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DBD currently has a P/E ratio of 27.99, whereas BRUN's P/E ratio is -101.33. In terms of profitability, DBD's ROE is +0.10%, compared to BRUN's ROE of N/A. Regarding short-term risk, DBD is less volatile compared to BRUN. This indicates potentially lower risk in terms of short-term price fluctuations for DBD.Check BRUN's competition here
DBD vs FRSH Comparison June 2026
DBD plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DBD stands at 2.8B. In comparison, FRSH has a market cap of 2.7B. Regarding current trading prices, DBD is priced at $81.14, while FRSH trades at $9.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DBD currently has a P/E ratio of 27.99, whereas FRSH's P/E ratio is 15.92. In terms of profitability, DBD's ROE is +0.10%, compared to FRSH's ROE of +0.19%. Regarding short-term risk, DBD is less volatile compared to FRSH. This indicates potentially lower risk in terms of short-term price fluctuations for DBD.Check FRSH's competition here
DBD vs NP Comparison June 2026
DBD plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DBD stands at 2.8B. In comparison, NP has a market cap of 2.7B. Regarding current trading prices, DBD is priced at $81.14, while NP trades at $28.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DBD currently has a P/E ratio of 27.99, whereas NP's P/E ratio is -156.03. In terms of profitability, DBD's ROE is +0.10%, compared to NP's ROE of -0.11%. Regarding short-term risk, DBD is less volatile compared to NP. This indicates potentially lower risk in terms of short-term price fluctuations for DBD.Check NP's competition here
DBD vs CALX Comparison June 2026
DBD plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DBD stands at 2.8B. In comparison, CALX has a market cap of 2.5B. Regarding current trading prices, DBD is priced at $81.14, while CALX trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DBD currently has a P/E ratio of 27.99, whereas CALX's P/E ratio is 81.17. In terms of profitability, DBD's ROE is +0.10%, compared to CALX's ROE of +0.04%. Regarding short-term risk, DBD is less volatile compared to CALX. This indicates potentially lower risk in terms of short-term price fluctuations for DBD.Check CALX's competition here